Food Revolution Group cashed up for a sustained growth in 2021
Hot on the heels of releasing impressive sales data across its Juice Lab Wellness Shots lines and bringing on board its largest customer in Woolworths, The Food Revolution Group Limited (ASX:FOD) has secured an investment of $3 million from two strategic global institutions via Evolution Capital Advisors.
This will assist in supporting the company’s s rollout of the Juice Lab Wellness range, as well as funding the group’s new cleanroom plant and equipment, effectively fast-tracking the introduction of more wellness supplements from the new facility.
There will also be benefits in transitioning the company’s overall financing as FOD emerges with a strengthened balance sheet from the placement of approximately 85.7 million shares at an issue price of 3.5 cents.
While the issue price represents a 14% discount to the last closing price of 4 cents, it needs to be borne in mind that the company’s shares have performed extremely strongly in March, increasing 45% from 2.8 cents on March 4 to last week’s close of 4 cents.
Management also pointed to debt refinancing initiatives that would be undertaken under the new structure, a development that is likely to see improved borrowing terms and potentially less of an earnings drag in terms of finance costs.
FOD uses a range of processing technologies, including Current Counter Extraction (CCE) technology which was developed in conjunction with Australia’s CSIRO to extract juice from fruit and vegetables.
The company is aiming to generate shareholder value through exploring opportunities for growth in the functional food, beverage and nutraceutical markets in Australian and key international markets, including China.
Consequently, a strengthening in FOD’s financial position is timely as it will provide the company with the capital to undertake initiatives in areas of product development and upscaling to cater for increased volumes, as well as marketing established and new products in Australia and overseas.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.